接受癌症治疗患者的丙型肝炎病毒再激活:一项前瞻性观察性研究
该前瞻性观察性研究纳入2012年11月至2016年7月在本机构接受癌症治疗的100例HCV感染者,再激活定义为HCV-RNA较基线升高≥1 log10 IU/mL,23例(23%)发生再激活,血液系统恶性肿瘤36%、实体瘤10%;利妥昔单抗和高剂量类固醇为独立预测因素;再激活者多数临床过程平稳,但可影响癌症治疗计划。
要点
- 接受癌症治疗的HCV感染者中23%发生再激活,血液系统恶性肿瘤36%高于实体瘤10%。
- 利妥昔单抗(OR=9.52)和高剂量类固醇(OR=5.05)为再激活的独立预测因素。
- 再激活者中43%出现肝炎 flare,但36周内无肝衰竭或肝相关死亡。
核心结论
- 接受癌症治疗的HCV感染者中23%发生再激活,多数临床过程平稳,但再激活可影响癌症治疗计划。
- 作者认为HCV感染不应成为癌症治疗的禁忌,感染者应能接受多种癌症治疗,并在接受与HCV再激活相关的方案时密切监测。
研究设计与样本
- 前瞻性观察性研究,纳入2012年11月至2016年7月在本机构接受癌症治疗的HCV感染者100例,其中血液系统恶性肿瘤50例、实体瘤50例。
- 再激活定义为HCV-RNA较基线升高≥1 log10 IU/mL;肝炎 flare 定义为丙氨酸氨基转移酶升高至正常上限的≥3倍。
主要发现
- 100例中23例(23%)发生再激活,其中血液系统恶性肿瘤18例(36%)、实体瘤5例(10%)。
- 单因素分析中,再激活者较无再激活者更常见 prolonged lymphopenia(中位95天 vs 22天,P=0.01)、接受利妥昔单抗(44% vs 9%,P<0.0001)、苯达莫司汀(22% vs 0%,P<0.001)、高剂量类固醇(57% vs 21%,P=0.001)或嘌呤类似物(22% vs 5%,P=0.02)。
- 多因素分析中利妥昔单抗(OR=9.52,P=0.001)和高剂量类固醇(OR=5.05,P=0.01)保持显著。
- 23例再激活者中10例(43%)出现肝炎 flare;再激活者在癌症治疗开始后36周内无肝衰竭或肝相关死亡。
- 14例肝炎 flare 患者(其中6例有再激活)需要中断或减量癌症治疗。
临床怎么用
- 作者认为HCV感染不应成为癌症治疗的禁忌,感染者应能接受多种癌症治疗。
- 作者建议在接受与HCV再激活相关的方案时密切监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in retrospective studies. We sought to determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment. HCV-infected patients receiving cancer treatment at our institution between November 2012 and July 2016 were studied. Reactivation was defined as an increase in HCV-RNA ≥1 log10 IU/mL over baseline and hepatitis flare as an increase in alanine aminotransferase to ≥3 times the upper limit of normal. One hundred patients were studied, 50 with hematologic malignancies and 50 with solid tumors. Reactivation occurred in 23 (23%) patients, including 18 (36%) patients with hematologic malignancies and 5 (10%) patients with solid tumors. In univariate analysis, patients with reactivation were more likely than those without reactivation to have prolonged lymphopenia (median, 95 versus 22 days; P = 0.01) and to have received rituximab (44% versus 9%; P < 0.0001), bendamustine (22% versus 0%; P < 0.001), high-dose steroids (57% versus 21%; P = 0.001), or purine analogs (22% versus 5%; P = 0.02). Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in multivariable analysis. Of the 23 patients with reactivation, 10 (43%) had hepatitis flare. No patient with reactivation experienced liver failure or liver-related death within 36 weeks after initiation of cancer treatment. Fourteen patients with hepatitis flare, six of whom had reactivation, required discontinuation or dose reduction of cancer treatment. CONCLUSION: HCV reactivation occurred in 23% of HCV-infected patients receiving cancer treatment, and most had an unremarkable clinical course. However, reactivation can affect the cancer treatment plan. Our findings suggest that HCV infection should not contraindicate cancer therapy and infected patients should have access to multiple cancer treatments with close monitoring while receiving regimens associated with HCV reactivation. (Hepatology 2018;67:36-47).
引用
- Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology. 2017. PMID: 28653760. doi:10.1002/hep.29344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。